AstraZeneca's MedImmune looks to UCSF for some good science and promising ideas

MedImmune, AstraZeneca's ($AZN) biologics arm, had inked a three-year agreement with the University of California, San Francisco, tapping the school's roster of scientists with hopes of finding promising projects across a bevy of disease areas. Under the deal, MedImmune will call on the expertise of UCSF's Clinical and Translational Science Institute, fielding applications from university scientists looking to get their discoveries out of academia and into development. The company said it will ask for proposals in areas including cardiovascular and metabolic disease; oncology; respiratory, inflammation and autoimmunity; neuroscience; and infectious disease. More

Suggested Articles

The deal gives J&J a stake in the development and commercialization of anticoagulants including phase 2-ready secondary stroke candidate BMS-986177.

Boehringer gained the global rights to OSE's SIRP-alpha antagonist, which is in development for solid tumors.

Lilly is diving into encapsulated beta cell treatments, designed to restore insulin production in patients with Type 1 diabetes.